



Clinically recognized sepsis in older adults admitted to medical wards: patient characteristics and hospital outcomes from the REPOSI register

Marta Chiara Sircana¹ · Alfredo Caturano² · Mauro Tettamanti³ · Sara Ratti^{3,6} · Chiara Ronchetti³ · Alessandro Nobili³ · Francesca Innocenti⁴ · Pier Mannuccio Mannucci⁵ · Roberto Manetti¹ · REPOSI Investigators

Received: 28 March 2026 / Accepted: 12 August 2026
© The Author(s) 2026

Abstract

Older adults admitted to internal medicine wards represent a growing population at high risk of sepsis, characterized by frailty, multimorbidity, functional impairment and reduced physiological reserve. While sepsis outcomes have been extensively studied in intensive care settings, less is known about prognostic determinants in non-ICU wards. Using data from the Italian REPOSI registry (2009–2023), we analyzed patients aged ≥ 65 years hospitalized in internal medicine and geriatric wards. Clinically recognized sepsis was identified through documented clinical diagnoses and corresponding ICD-9 codes. Latent Class Analysis (LCA) was used to explore multimorbidity patterns within the sepsis cohort. The primary aim was to evaluate factors associated with in-hospital mortality in older adults with sepsis. Secondary analyses compared baseline characteristics between septic and non-septic cases, assessed in-hospital mortality determinants according to sepsis onset setting (community- vs hospital-acquired), and explored factors associated with prolonged length of stay (LOS) in community-acquired sepsis. Additional descriptive analyses evaluated geographic distribution, infection sources and treatment patterns. Among 8880 patients, 504 (5.7%) had clinically recognized sepsis; more than half were hospital-acquired. In-hospital mortality was high (23.8%) and markedly higher in hospital-acquired sepsis. Two distinct multimorbidity patterns emerged: an oncologic–hepatologic profile and a diffuse chronic multimorbidity profile characterized by cardio–renal–metabolic, respiratory, and neuropsychiatric conditions. In community-acquired sepsis, the chronic multimorbidity profile was independently associated with increased mortality, whereas this association was not observed in hospital-acquired sepsis. Across the cohort, advanced age, functional dependence and hypoalbuminemia emerged as key factors independently associated with in-hospital mortality. Exploratory LOS analyses in community-acquired sepsis showed a modest association between prolonged hospitalization and higher anticholinergic burden. Additional descriptive analyses showed that lower respiratory tract infections were the most frequent source of both community- and hospital-acquired sepsis, while hospital-acquired cases showed greater heterogeneity of infectious sources and treatment patterns. In internal medicine wards, clinically recognized sepsis in older adults may reflect underlying clinical vulnerability rather than an isolated acute event. Multimorbidity patterns and geriatric-related clinical dimensions appear to influence outcomes, particularly in community-acquired sepsis. Integrating multimorbidity, nutritional and functional assessments into sepsis evaluation may improve risk stratification and support more personalized management in older hospitalized patients.

Keywords Sepsis · Older adults · Internal medicine · Multimorbidity · Frailty · Latent class analysis

✉ Roberto Manetti
rmanetti@uniss.it

¹ Department of Medicine, Surgery and Pharmacology, University of Sassari, 07100 Sassari, Italy

² Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma University, 00166 Rome, Italy

³ Department of Health Policy, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milan, Italy

⁴ Center for Advanced Simulation in Medicine, University Hospital Careggi, Lg. Brambilla 3, 50134 Florence, Italy

⁵ A. Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca' Granda Maggiore Hospital Foundation, and University of Milan, Milan, Italy

⁶ Present Address: Department of Clinical Research, University of Bern, Bern, Switzerland

Introduction

Sepsis is a major clinical challenge in internal medicine wards, where the hospital population is predominantly older, multimorbid and clinically vulnerable [1, 2]. In this setting, sepsis often develops subacutely, with subtle and atypical features that may delay diagnosis and treatment in patients with a complex clinical pattern, where organ dysfunction intertwines with frailty, comorbidities, functional impairment and iatrogenic factors [3].

Although extensively investigated in intensive care units (ICUs), the burden of sepsis in internal medicine wards remains relatively underexplored, despite high mortality, disability, and prolonged hospital stays [4, 5].

Emerging evidence indicates that sepsis is a biologically heterogeneous condition with distinct clinical phenotypes influenced by the type of pathogens, infection sources and comorbidity patterns. This heterogeneity contributes to variable outcomes, underscoring the need for integrated stratification models capturing clinical complexity, multimorbidity and geriatric vulnerability.

At an epidemiological level, both incidence and mortality of sepsis are increasing in Europe, with an estimated 400,000 – 800,000 sepsis cases each year and a fatality rate between 15 and 25% [5]. In Italy, sepsis-related deaths increased from 18,939 (3%) in 2003 to 49,010 (8%) in 2015, in parallel with population aging, multimorbidity, invasive procedures, and antimicrobial resistance [6].

The Sepsis-3 definition framed sepsis as a life-threatening organ dysfunction caused by a dysregulated host response to infection [7]. However, in older adults, commonly used scores (qSOFA, SOFA, SIRS, NEWS) rely heavily on vital signs and show limited sensitivity in this age group, where physiological responses are often blunted, and they fail to capture functional reserve [8, 9].

Geriatric domains including multimorbidity, nutritional and functional status are strong prognostic determinants and should be incorporated into risk stratification [10–12]. Since vulnerability is driven by specific combinations of comorbidities rather than their mere number, person-centered analytical approaches such as the Latent Class Analysis (LCA) are particularly suitable [13].

From these premises and gaps of knowledge, the present study, based on the Italian REPOSI registry, aimed to characterize clinically recognized sepsis in older adults hospitalized in internal medicine wards, with particular focus on multimorbidity patterns and in-hospital mortality. Secondary analyses explored determinants of in-hospital mortality according to sepsis onset (community-acquired vs hospital-acquired) and factors associated with prolonged length of stay in community-acquired sepsis, while additional descriptive analyses assessed infection sources,

antimicrobial treatment patterns, and geographical distribution within the registry.

Methods

Study design

This retrospective study is based on data from the REPOSI (REgistro POLiterapie SIMI) registry, an ongoing collaborative initiative launched in 2008 by the Italian Society of Internal Medicine (SIMI), the Istituto di Ricerche Farmacologiche Mario Negri IRCCS, and the Fondazione Ospedale Policlinico IRCCS Ca' Granda Maggiore. The registry involves multiple internal medicine and geriatric hospital wards across Italian regions. Detailed information on the REPOSI project has been reported in Mannucci et al. [14].

Patients aged 65 years and older were recruited. Recruitment took place during four predefined index weeks each year. Written informed consent was obtained from all participants prior to enrolment. The study protocol was approved by the ethics committee of each participating center. Information on health status, clinical events and drug therapy were recorded at admission, during hospital stay, and at discharge. Functional status (Barthel Index), nutritional status as estimated by serum albumin, and other clinical and laboratory variables were assessed at hospital admission and used as baseline indicators for the analyses. Frailty was assessed using a Frailty Index based on the deficit accumulation approach proposed by Rockwood and Mitnitski and previously implemented in the REPOSI registry [15, 16]. The index incorporates socio-demographic, physical, cognitive, functional, and clinical deficits and provides a quantitative measure of biological vulnerability, with higher scores indicating greater frailty. The REPOSI registry collects clinical and laboratory data at admission and at discharge from internal medicine wards and does not capture clinical status at sepsis onset. Consequently, available data do not allow assessment of acute illness severity at sepsis onset (e.g., full SOFA score), because in patients with sepsis present at admission they reflect post-emergency department conditions, no measurements being available at the onset of hospital-acquired sepsis. All diseases were classified according to the International Classification of Diseases, 9th revision (ICD-9) and all drugs were coded using the Anatomical Therapeutic Chemical (ATC) classification system [17, 18].

The initial analytical cohort comprised 10,253 individuals enrolled in the REPOSI registry between 2008 and 2023.

For the purposes of this analysis, cases enrolled in the 2008 edition of the registry ($n=1332$) were excluded, as the Cumulative Illness Rating Scale (CIRS) was not collected on that year by study design. Additionally, patients with missing, inconsistent, or clearly erroneous data

regarding either CIRS scores or medication use at the time of hospital admission were excluded (n=41). Thus, the final study cohort consisted of 8880 individuals (Fig. 1).

Inclusion in the sepsis group required a documented sepsis diagnosis from at least one of the following sources: reason for hospitalization, admission diagnoses, indication for drug therapy, intercurrent clinical events during hospitalization, or cause of death. Sepsis cases were identified using ICD-9 codes (Supplementary Table S1). Additional registry labels for severe sepsis and septic shock were extracted.

Baseline comorbidities were defined using ICD-9 codes as follows: malignancy (140–208), chronic respiratory disease (491, 493, 515, 518), chronic heart disease and hypertensive heart and renal disease (402, 404, 428), chronic kidney disease (585), diabetes mellitus (250), chronic liver disease (571, 070), and neuropsychiatric disorders (433, 434, 438, 348, 290, 291, 340, 335, 357, 332).

Antimicrobial treatment for sepsis was classified according to ATC groups J01 and J02, and vasoactive agents [adrenaline (C01CA24), noradrenaline (C01CA03)] and dopamine (C01CA04) were also considered (Supplementary Table S2).


To further characterize sepsis, the most likely source of infection was identified by reviewing multiple records within the REPOSI registry and classified into predefined categories, including lower respiratory tract, urinary tract, intra-abdominal, gallbladder, skin or soft tissue, septic arthritis, cardiac or unknown origin, based on corresponding ICD-9 codes (Supplementary Table S1). Because of the structure of the REPOSI registry, catheter-related bloodstream infections (CRBSI) and other device-associated infections could not be identified as distinct causes of sepsis.

Statistical analysis

Patients baseline characteristics, drug therapy, comorbidities and clinical parameters at admission were described using frequencies and percentages for categorical variables, and medians with interquartile ranges for continuous ones. Group differences were assessed using chi-square tests for categorical variables and Wilcoxon rank-sum tests for continuous ones and reporting p-values.

The primary aim of the study was to evaluate factors associated with in-hospital mortality in older adults with clinically recognized sepsis admitted to Internal Medicine

Fig. 1 Flow-chart of the population selection



wards. Secondary analyses compared baseline characteristics between septic and non-septic cases and assessed mortality determinants according to sepsis onset setting (community- vs hospital-acquired). We also explored prolonged length of stay (LOS), measured as days from admission to discharge or death dichotomized according to the median value, but only for cases of in sepsis diagnosed at admission, because LOS in hospital-acquired sepsis may reflect hospitalization preceding sepsis onset. Additional descriptive analyses assessed geographic distribution, infection sources and treatment patterns.

Latent Class Analysis (LCA) was applied to identify homogeneous multimorbidity subgroups among patients presenting with at least two chronic conditions, which were compared with those with no/low comorbidity. LCA is a probabilistic, model-based clustering technique that assigns individuals to mutually exclusive groups according to the similarity of their response patterns across observed variables [19]. The model included seven chronic conditions recorded at admission: malignancy, chronic respiratory disease, chronic heart failure, hypertensive heart and renal disease, chronic kidney disease, chronic liver disease, neuropsychiatric disorders and diabetes mellitus. The analysis included 229 patients presenting two or more of these comorbidities, whereas patients with none or one comorbidity ($n=275$) were grouped into a “*No/Low Comorbidity category*” and used as the reference group in subsequent analyses.

The optimal number of classes was determined by balancing statistical fit and clinical interpretability, using the Bayesian Information Criterion (BIC) and the Akaike Information Criterion (AIC). Class assignment and characterization were based on posterior probabilities, observed-to-expected ratios (O/E), and exclusivity measures (Supplementary Tables S7–S8).

Class composition was assessed using O/E ratios and exclusivity, which reflect the relative overrepresentation of conditions within each class. Conditions were considered part of a class pattern if the O/E ratio was ≥ 1.5 or exclusivity $\geq 25\%$, and the latent classes were named accordingly.

The latent classes identified in the final model were used to create a categorical variable, which was included as a predictor in subsequent analyses. Participants with 0–1 comorbidity, who were not included in the LCA, were considered as the reference group to allow comparison with multimorbid patients.

Associations between variables and outcomes were first explored using univariate logistic regression. Multivariable models were adjusted for age and sex, and then for relevant clinical covariates: Barthel index, serum albumin, serum glucose, body mass index (BMI), anticholinergic drug cognitive burden (ACB) index, admission year

(2010–2016 vs. 2017–2023), and LCA class membership [20]. For each model, odds ratio (OR), 95% confidence intervals (CIs) and p-values were reported. To improve interpretability, selected continuous variables were rescaled before inclusion in regression models: glucose was modelled per 10-mg/dl increase and Barthel Index per 10-point increase. Missing data were handled through multiple imputation, performed using chained equations applied to albumin, glucose, BMI and Barthel index, with the goal to preserve statistical power given the moderate sample size.

All analyses were performed using Stata/IC v15.1 (StataCorp, College Station, TX).

Results

General characteristics of the study population

Among the 8880 patients included in the study, 504 (5.7%) had a diagnosis of sepsis: 219 cases (43.5%) were community-acquired, while the majority (285 cases, 56.5%) developed sepsis during hospitalization (Fig. 1). Differences according to sepsis setting onset were observed. Hospital-acquired sepsis was associated with higher in-hospital mortality compared with community-acquired sepsis, respectively 36.1% vs. 14.9% (Supplementary Tables S9–S10). In addition, multimorbidity patterns showed differential prognostic relevance according to the sepsis onset setting. The chronic multimorbidity profile identified by LCA (class 2) was independently associated with in-hospital mortality in community-acquired sepsis, whereas no significant association was observed in hospital-acquired cases (Supplementary Tables S9–S10).

Within the sepsis cohort, 51 patients had a documented diagnosis of septic shock and 95 of severe sepsis according to the registry coding in use during the study period.

Table 1 reports the characteristics of the study population, stratified by the presence or absence of sepsis. Patients with sepsis were, on average, older, with lower Barthel Index scores, higher clinical frailty scores, greater comorbidity burden at admission, were more frequently admitted from residential facilities rather than home and were often previously hospitalized within the previous 12 months. In addition, patients with sepsis more frequently exhibited hypoalbuminemia, neuropsychiatric and neoplastic diseases, greater need for urinary catheterization during hospitalization, and had a longer length of stay. Geographical and temporal analyses revealed a relatively higher prevalence of sepsis in Northern regions and during the 2017–2023 period (Table 1).

Table 1 Demographic and clinical characteristics of patients with and without sepsis (N = 8880)

Variable	No Sepsis (n = 8376)	Sepsis (n = 504)	p-value ^a
Age (years), median (IQR)	80 (74–85)	82 (75–87)	<0.001
Gender, n (%)			0.27
Female	4234 (50.5)	242 (48.0)	
Male	4142 (49.5)	262 (52.0)	
Length of Stay (days), median (IQR)	9 (6–14)	14 (8–22)	<0.001
Origin, n (%)			<0.001
Home	7811 (94.4)	440 (88.5)	
Nursing home	237 (2.9)	37 (7.4)	
Other (specify)	222 (2.7)	20 (4.0)	
Ward, n (%)			0.22
Geriatrics	1624 (19.4)	109 (21.6)	
Internal Medicine	6,752 (80.6)	395 (78.4)	
Region, n (%)			0.002
North	3793 (45.3)	268 (53.2)	
Center	2268 (27.1)	113 (22.4)	
South and Islands	2315 (27.6)	123 (24.4)	
Previous 12 months hospital admissions, n (%)	2841 (34.0)	232 (46.1)	<0.001
Frailty index, median (IQR)	7.5 (5.8–10)	9.5 (7–12.5)	<0.001
Barthel index before admission, median (IQR)	91 (68–100)	73 (31–96)	<0.001
Albumin (g/dl), median (IQR)	3.4 (3.0–3.8)	3.0 (2.5–3.3)	<0.001
Glucose (mg/dl), median (IQR)	108 (91–138)	113 (92–144)	0.065
Body Mass Index (BMI) (kg/m ²), median (IQR)	25.35 (22.58–28.44)	24.61 (22.10–27.68)	0.004
ACB index, median (IQR)	10 (0–22)	14 (0–29)	<0.001
Malignancy, n (%)	1194 (14.3)	113 (22.4)	<0.001
Chronic Respiratory disease, n (%)	711 (8.5)	34 (6.7)	0.17
Heart failure, n (%)	2561 (30.6)	152 (30.2)	0.84
Renal diseases, n (%)	1815 (21.7)	134 (26.6)	0.01
Diabetes, n (%)	2,302 (27.5)	131 (26.0)	0.47
Chronic liver diseases, n (%)	821 (9.8)	43 (8.5)	0.35
Neuropsychiatric diseases, n (%)	1913 (22.8)	161 (31.9)	<0.001
CIRS severity at admission, median (IQR)	1.62 (1.38–1.85)	1.69 (1.46–1.92)	<0.001
CIRS comorbidity at admission, median (IQR)	3 (2–4)	3 (2–4)	0.001
N. of drugs, median (IQR)	5 (4–8)	6 (4–8)	0.80
Polytherapy, n (%)	5242 (62.6)	322 (63.9)	0.56
Urinary catheter at admission, n (%)			<0.001
No	7848 (95.4)	423 (85.8)	
Yes	381 (4.6)	70 (14.2)	
Admission Year, n (%)			<0.001
2010–2016	4504 (53.8)	161 (31.9)	
2017–2023	3872 (46.2)	343 (68.1)	

Data are presented as number (percentage) [n (%)] for categorical variables or median (interquartile range) [median (IQR)] for continuous variables unless otherwise specified

^a p-values were obtained using the Wilcoxon rank-sum test for continuous variables and the chi-square test for categorical variables

BMI Body Mass Index, **IQR** Interquartile Range, **CIRS** Cumulative Illness Rating Scale, **ACB** Anticholinergic Cognitive Burden

Missing values: Length of stay (n=20); Origin (n=113); Previous hospital admissions (n=9); Barthel Index (n=1,528); Albumin (n=3,208); Glucose (n=460); BMI (n=1,232); CIRS (n=14); Urinary catheter (n=158)

Latent class analysis (LCA)

LCA identified two multimorbidity patterns with at least two selected chronic conditions. The first, *Oncologic–Hepato-logic*, was characterized by a high prevalence of malignancy and chronic liver diseases with limited co-occurrence of other chronic conditions. The second, *Chronic Multimorbidity*, included patients with predominant chronic respiratory disorders frequently coexisting with cardio-renal-metabolic and neuropsychiatric comorbidities. Patients with no/low comorbidity were retained as the reference group.

Further details are provided in Supplementary Table S7–S8.

Mortality

In-hospital mortality was higher in patients with sepsis than in non-septic cases (23.8% vs 3.0%; Table 1). Among patients with sepsis with available discharge outcome, mortality differed markedly according to sepsis onset setting, being more than twice in sepsis developed during hospitalization than in sepsis already present at admission (36.1% vs.

14.9%; 91/252 vs. 29/194). Notably, the excess in-hospital mortality observed among patients with sepsis was largely driven by hospital-acquired episodes, which were associated with a substantially higher risk of death compared with community-acquired sepsis.

In the multivariate analysis (Table 2), three admission variables were independently associated with in-hospital mortality among patients with sepsis: advanced age (OR 1.05; 95% CI 1.02–1.09; $p = 0.001$), lower Barthel Index (OR 0.90 per 10-point increase; 95% CI 0.90–1.00; $p = 0.02$), and lower albumin levels (OR 0.59 per 1 g/dL increase in serum albumin; 95% CI 0.36–0.97; $p = 0.043$). A borderline association with lower in-hospital mortality was also observed for admissions during 2017–2023 compared with 2010–2016 (OR 0.61; 95% CI 0.37–0.99; $p = 0.05$).

When analyses were stratified by sepsis onset setting, different mortality patterns emerged: in community-acquired sepsis, age and Barthel Index remained significant predictors of mortality, in line with the overall septic cohort, whereas serum albumin levels were not (Supplementary Table S9). In this subgroup, multimorbidity phenotypes identified by LCA were variably associated with mortality: compared with the reference group,

Table 2 Association of patient characteristics with in-hospital mortality in sepsis: logistic regression model (N = 446)

Variable	Discharged (n = 326)	Dead (n = 120)	Univariate OR (95% CI)	Multivariate OR (95% CI)	p-value ^a
Age (years), mean ($\pm$ SE)	80.1 (0.4)	83.7 (0.7)	1.06 (1.03–1.10)	1.05 (1.02–1.09)	0.001***
Barthel index (per 10-point increase), mean ($\pm$ SE)	66.1 (2.0)	49.5 (3.7)	0.90 (0.82–0.90)	0.90 (0.90–1.00)	0.02*
Albumin (g/dL), mean ($\pm$ SE)	3.0 (0.1)	2.8 (0.1)	0.49 (0.32–0.76)	0.59 (0.36–0.97)	0.04*
Glucose (per 10 mg/dL increase), mean ($\pm$ SE)	131.1 (4.2)	131.9 (6.9)	1.00 (1.00–1.00)	1.00 (1.00–1.00)	0.99
BMI (kg/m ²), mean ($\pm$ SE)	25.1 (0.3)	24.4 (0.5)	0.97 (0.92–1.02)	0.989 (0.94–1.05)	0.76
ACB index, mean ($\pm$ SE)	20.7 (1.5)	27.3 (2.8)	1.01 (1.00–1.01)	1.01 (1.00–1.01)	0.06
Gender, n (%)					
Female (Ref.)	151 (46.3)	59 (49.2)	Ref	Ref	0.66
Male	175 (53.7)	61 (50.8)	0.89 (0.59–1.36)	1.07 (0.67–1.68)	
Admission Year, n (%)					
2010–2016 (Ref.)	103 (31.6)	45 (37.5)	Ref	Ref	0.05*
2017–2023	223 (68.4)	75 (62.5)	0.77 (0.50–1.19)	0.61 (0.37–0.99)	
LCA class, n (%)					
No/Low comorbidity (Ref.)	189 (58.0)	52 (43.3)	Ref	Ref	0.07
Oncologic–liver disease	45 (13.8)	21 (17.5)	1.70 (0.93–3.10)	2.01 (1.05–3.85)	
Chronic multimorbidity with respiratory involvement	92 (28.2)	47 (39.2)	1.86 (1.16–2.96)	1.51 (0.91–2.54)	

All models were developed using Multiple Imputation to handle missing data for Barthel Index, Albumin, Glucose and BMI

Continuous variables are presented as mean (standard error) and categorical variables are expressed as frequencies (percentage). Odds ratios refer to a one-unit increase unless otherwise specified; for glucose, odds ratios refer to a 10 mg/dL increase; for the Barthel Index to a 10-point increase

Global p-value of the multivariate model (chi-square test): <0.0001

SE Standard Error, OR Odds Ratio, CI Confidence Interval, LCA Latent Class Analysis, BMI Body Mass Index, ACB Anticholinergic Cognitive Burden, Ref. Reference Category

^a p-value refers to the multivariate analysis: * $p < 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$

The analysis includes 446 septic patients; 58 patients transferred to other wards or hospitals were excluded due to unavailable in-hospital outcome

the chronic multimorbidity class was associated with higher odds of death (OR 4.34; 95% CI 1.45–12.96; $p = 0.03$), whereas cases in the oncologic–hepatologic class showed no statistically significant increase in mortality (OR 2.78; 95% CI 0.64–12.05). These associations were not observed in the overall septic cohort (Table 2). In contrast, in hospital-acquired sepsis, age was the only variable independently associated with in-hospital mortality (Supplementary Table S10).

Length of hospital stay (LOS)

Median LOS was longer among patients with sepsis than in non-septic cases (14 days [IQR 8–22] vs. 9 days [IQR 6–14], $p < 0.001$) (Table 1). Because the exact timing of sepsis onset was unavailable for hospital-acquired cases, LOS analyses were considered to be more appropriately interpretable in community-acquired sepsis. In this subgroup, prolonged LOS was independently associated with a higher anticholinergic drug burden (OR 1.02 per one-point increase; 95% CI 1.00–1.03; $p = 0.013$), while age, Barthel Index score, serum albumin levels and LCA class were not (Supplementary Table S11).

Source of sepsis

Source identification differed between community-acquired and hospital-acquired sepsis, being available in 42% and 67% of cases, respectively (Supplementary Tables S3–S4). In both settings, lower respiratory tract infections were the most common source (32 and 29%), followed by urinary (16 and 18%), intra-abdominal (15% in both), and hepatobiliary infections. Hospital-acquired sepsis showed a broader spectrum of sources, including skin and soft tissue, as well as cardiac infections.

Pharmacological therapies

Across the study period, the most frequently used antimicrobials were β -lactam/ β -lactamase inhibitor combinations, followed by third-generation cephalosporins, carbapenems, glycopeptides, and fluoroquinolones; triazoles/tetrazoles predominated among antifungals. Between 2010–2016 and 2017–2023 the use of carbapenems and fluoroquinolones declined, while prescriptions of other antibacterial agents (e.g., linezolid, daptomycin, fosfomycin) increased moderately (Supplementary Tables S5a–S5b). Vasoactive amines were rarely employed (Supplementary Tables S5a–S5b–S6).

Discussion

Older adults with clinically recognized sepsis admitted to internal medicine and geriatric wards represent a clinically complex population at high risk of adverse outcomes.

While research on sepsis has predominantly focused on ICU, its burden and determinants in internal medicine wards remain comparatively underexplored, despite substantial mortality, disability, and prolonged hospital stay [31]. Using data from the REPOSI registry, this retrospective study provides a real-world description of sepsis burden and outcomes, including in-hospital mortality and length of stay [3].

Sepsis burden in internal medicine wards

The prevalence of clinically recognized sepsis in our cohort (5.7%) aligns with previous European studies conducted in internal medicine wards, with reported rates ranging between 4 and 6% [21–23]. The higher prevalence observed in 2017–2023 likely reflects the increased awareness of sepsis following the introduction of Sepsis-3 criteria. The higher prevalence recorded in Northern Italy may reflect regional demographic differences, participating centres distribution, local healthcare organization and patient case-mix, and temporal factors including the COVID-19 pandemic. More than half of sepsis cases developed during hospitalization, underscoring hospital-acquired sepsis as a major clinical problem in medical wards, where it was associated with prolonged hospitalization and substantially higher mortality than community-acquired sepsis.

Distinct predictors of in-hospital mortality emerged according to the sepsis onset setting. Community-acquired sepsis appeared associated with age, functional impairment and multimorbidity phenotype, whereas age remained the predominant determinant of in-hospital mortality in hospital-acquired sepsis.

Clinical vulnerability, frailty and multimorbidity

Compared with non-septic patients, those with sepsis exhibited greater frailty, multimorbidity, functional impairment and reduced physiological reserve [15, 24]. Advanced age emerged as the strongest independent predictor of in-hospital mortality, confirming its central prognostic role in older adults with sepsis. Cancer-related immunosuppression and healthcare exposure may increase susceptibility to infection and poor outcomes, while neuropsychiatric disorders may contribute through functional impairment, delayed symptom recognition and anticholinergic drug burden [25, 26]. Taken together, these observations suggest that, in older adults, ward-managed sepsis frequently occurs at the intersection of infection and pre-existing vulnerability [27].

The application of LCA identified two main classes: an oncologic–hepatologic profile and a chronic multimorbidity profile characterized by cardio–renal–metabolic, respiratory,

and neuropsychiatric diseases. These classes should be interpreted as statistically derived, context-dependent constructs rather than definite biological endotypes. Their composition reflects the variables available within the registry and may differ in other populations. Nevertheless, they provide a clinically meaningful framework for characterizing vulnerability heterogeneity and may complement traditional risk stratification approaches. Comparable applications of LCA have been previously reported in sepsis research, both in acute cohorts and among sepsis survivors [28, 29].

Determinants of in-hospital mortality

Overall in-hospital mortality among patients with sepsis was high (23.8%), consistently with the upper range reported in European cohorts (15–25%), and was markedly higher in hospital-acquired sepsis (36.1%) [4, 41]. This estimate is also consistent with the pooled 30-day mortality of 23.6% reported for European studies in a large international systematic review and meta-analysis [30]. Our findings complement the limited evidence from internal medicine and general ward cohorts, where sepsis is associated with substantial mortality and remains considerably less studied than in emergency department and ICU populations [22].

Advanced age, functional impairment, and hypoalbuminemia confirmed the prognostic relevance of baseline vulnerability in older adults with sepsis in the overall cohort. Lower levels of albuminemia should be interpreted as a marker of vulnerability rather than a therapeutic target, as its prognostic value does not imply benefit from albumin supplementation [32]. No consistent associations were observed between mortality and sex, BMI, or glycemic levels, in line with findings in the literature [33].

These findings should be interpreted in the light of the structure of the REPOSI registry, which was not specifically designed to capture acute physiological derangement at the time of sepsis onset. As a result, the observed associations primarily reflect baseline clinical vulnerability rather than acute illness severity. This interpretation should not imply that multimorbidity, functional impairment, or nutritional status outweigh acute illness severity in determining prognosis. Rather, acute severity and early management could not be adequately assessed within the present dataset. Therefore, our findings identify prognostic factors related to those of baseline clinical vulnerability which were observable in the frame of this ward-based population [34].

Distinct prognostic associations emerged according to sepsis onset. In community-acquired sepsis, mortality was associated with the chronic multimorbidity phenotype, whereas from the association for the oncologic–hepatologic class, a trend did not reach statistical significance. In line with large national cohort studies indicating that multimorbidity is associated with increased risk of sepsis and higher

in-hospital mortality, our findings suggest that multimorbidity may represent a marker of biological vulnerability rather than a mere clinical background [35]. Although advanced cancer and severe liver disease are established states of immune vulnerability, the broader chronic multimorbidity phenotype identified in the present cohort showed a stronger association with mortality in community-acquired sepsis [36, 37]. These observations suggest that specific combinations of chronic conditions, rather than their number alone, may shape prognosis in community-acquired sepsis. However, the direction of the association remained consistent with an increased mortality risk in the oncologic–hepatologic phenotype, although the lack of statistical significance may reflect the heterogeneity of this class, preferential referral of high-risk patients to specialized units, and limited statistical power owing to small sample size.

In contrast, in hospital-acquired sepsis, age remained the sole independent predictor of mortality, while baseline vulnerability markers did not retain independent prognostic significance. This may reflect the influence of time-dependent care processes, including early administration of proper antimicrobial therapy, prompt source identification and control, escalation of care including ICU transfer: factors that are not measured by the Registry, making the prognostic contribution of baseline vulnerability parameters less apparent [38]. Although SOFA scores were unavailable, exploratory analyses showed substantially higher mortality among patients with clinically documented severe sepsis/septic shock (41.5% vs. 17.3%), supporting the contribution of acute illness severity to prognosis. Residual confounding due to unmeasured severity variables (eg. lactate levels, full SOFA score) cannot be excluded.

Determinants of prolonged hospitalization

Median LOS was longer among patients with sepsis than non-septic cases (14 vs. 9 days), consistently with medical ward-based international studies [2]. Because the exact timing of sepsis onset was unavailable in hospital-acquired cases, LOS analyses were considered more interpretable in community-acquired sepsis. In this subgroup, prolonged LOS (> 14 days) was independently associated with higher anticholinergic drug burden (ACB index). Higher anticholinergic burden may contribute to longer hospitalization through increased risk of delirium, cognitive decline, falls, and functional deterioration. As such, it may represent a potentially modifiable target in hospitalized patients [39].

Infection sources and treatment patterns

Lower respiratory tract infections were the most frequent source of sepsis, followed by urinary tract, intra-abdominal, and hepatobiliary infections, in line with large international

cohorts [5, 40, 41]. Older adults are particularly susceptible to respiratory and urinary infections because of age-related vulnerability and multimorbidity [42, 43]. Source identification differed between community and hospital-acquired sepsis. In community-acquired cases, the source remained unidentified in more than half of patients, likely reflecting atypical presentations, delayed and limited access to early diagnostic investigations [44]. In hospital-acquired sepsis, respiratory and urinary infections remained prevalent, but a broader spectrum of sources was identified, including skin, soft-tissue, and cardiac infections, consistent with health-care-related exposures.

Antimicrobial therapy mainly relied on broad-spectrum antibiotics, such as β -lactams, cephalosporins, and carbapenems, consistent with international recommendations for initial sepsis management [45, 46]. Over time, fluoroquinolone, cephalosporin and antifungal drugs use declined, while more targeted agents such as fosfomycin, linezolid, and daptomycin use increased [47]. Despite the trend towards appropriateness, carbapenem use remained substantial even in community acquired sepsis, possibly reflecting concerns about multidrug resistant organisms in multimorbid patients. Antimicrobial treatment patterns were described for the overall as well as community-acquired sepsis cohorts, while analyses of hospital-acquired sepsis were limited by treatment changes during hospitalization. Vasopressor use was rare, reflecting the ward-based setting, where septic shock prompts ICU referral [45]. Increased noradrenaline use likely reflects evolving adherence to sepsis guidelines. These findings align with real-world studies from non-ICU settings, where vasopressors are used in fewer than 3% of cases and highlight differences from critical care settings [48].

Clinical implications and future directions

These findings indicate that, in internal medicine wards, sepsis may reflect the convergence of infection with multimorbidity, functional impairment, nutritional compromise, and pharmacological burden. LCA-derived multimorbidity patterns may help to identify subgroups of patients at differing risk of mortality and prolonged hospitalization. Integrating functional status, nutritional markers, and medication review into routine clinical assessment may improve risk stratification. Future studies should validate multimorbidity phenotypes in other cohorts, incorporate acute severity measures, and explore biological correlates of vulnerability in order to advance precision medicine approaches in geriatric sepsis.

Strengths and limitations

The main strengths of this study include its nationwide multicentre setting, large sample size, prolonged

observation period, and real-world representation of internal medicine and geriatric wards across Italy. The study is based on a retrospective analysis of prospectively collected data from the REPOSI registry, where consecutively enrolled patients are evaluated according to a standardized protocol using predefined clinical variables across participating centres. These design characteristics reduce selection and information bias, strengthen external validity, and provide a robust framework for investigating clinically recognised sepsis in routine internal medicine practice. The internal consistency of the identified sepsis cohort is further supported by the observed prevalence, antimicrobial treatment patterns and mortality, which are consistent with previous internal medicine cohorts. The study addresses an underexplored clinical setting, as most sepsis literature stems from ICU populations despite the growing burden of sepsis among older patients admitted to medical wards. This is particularly relevant given the distinctive biological and clinical features of older adults. The integration of functional, nutritional, pharmacological and multimorbidity-related variables together with the application of an innovative multimorbidity-based approach provides novel clinical insights.

Limitations include the retrospective design, possible sepsis misclassification related to ICD-9 coding, and the lack of availability of key acute-severity variables (e.g., CRP, lactate values, dynamic severity variables, full SOFA score), which limited Sepsis-3 adjudication and comparison of illness severity with ICU-based sepsis cohorts. Although several laboratory and physiological variables were available, they were generally recorded at ward admission rather than at sepsis onset and therefore could not reliably reflect the acute severity of the septic episode. Because REPOSI spans 2008–2023 and was designed to investigate a broad spectrum of medical conditions rather than any single disease or syndrome, it does not systematically collect all condition-specific variables required for retrospective diagnostic adjudication, including all SOFA components. Accordingly, sepsis identification relied on clinician-assigned ICD-9 coding retrieved from multiple predefined registry sections, rather than on hospital discharge codes alone, a strategy widely used in large epidemiological studies, but inherently liable to some degree of misclassification. As with other nationwide prospective registries, retrospective adjudication of every recorded diagnosis according to condition-specific diagnostic criteria was beyond the scope of the registry design. Consequently, the present findings should be interpreted as referring to clinically recognised sepsis rather than retrospectively adjudicated Sepsis-3-defined sepsis.

Similarly, the available dataset did not provide sufficient information to identify catheter-related bloodstream infections (CRBSI) or other device-associated infections as distinct etiological categories, preventing a more detailed

characterization of hospital-acquired sepsis [49]. Nevertheless, exploratory analyses showed higher mortality in clinician-documented severe sepsis/septic shock, consistently with the prognostic role of acute severity.

The REPOSI registry includes only patients admitted to internal medicine and geriatric wards, while patients with more severe acute presentations may be managed in intensive care units, whereas those with specific infectious or oncologic conditions and a lower burden of comorbidity may be preferentially admitted to specialized units. This setting-related selection may have influenced the case mix and the distribution of multimorbidity profiles, limiting generalizability of the identified multimorbidity phenotypes.

Finally, residual confounding, particularly in hospital-acquired sepsis, cannot be excluded because data on acute management were not available, including devices, fluid resuscitation, time-to-antibiotics, antibiotic appropriateness, and adequacy of hemodynamic support. In hospital-acquired sepsis, the exact timing of onset was unavailable, therefore, LOS may partly reflect hospitalization preceding sepsis onset rather than the sole impact of sepsis itself. Despite these limitations, the study provides relevant real-world insights into sepsis among elderly multimorbid patients admitted to internal medicine and geriatric wards.

Conclusion

In older adults admitted to internal medicine wards, sepsis may be understood and managed not merely as an acute infectious syndrome but as the clinical expression of an underlying vulnerability shaped by age, multimorbidity and treatment burden. Integrating geriatric dimensions into sepsis assessment may help identify high-risk patients and support more personalized management strategies.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s11739-026-04501-z>.

Acknowledgements Steering Committee: Pier Mannuccio Mannucci (Chair) (Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano), Alessandro Nobili (co-chair) (Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano), Nicola Montano (Presidente SIMI), Giorgio Sesti (Past-President—SIMI), Antonello Pietrangelo (Direttore CRIS—SIMI), Antonio De Vincentis (Policlinico Universitario Campus Bio-Medico, Roma), Alessandra Marengoni (Spedali Civili di Brescia, Brescia), Mauro Tettamanti, Luca Pasina, Carlotta Franchi (Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano). **Clinical Data Monitoring and Revision:** Francesca Orsini, Massimo Cartabia, Gabriella Miglio (Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano). **Database Management and Statistics:** Alessia Antonella Galbussera, Sara Mandelli, Ilaria Ardoino, Alessio Novella, Sara Ratti, Enrico Nicolis (Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano). **Investigators:** Domenico Prisco, Elena Silvestri, Giacomo Emmi, Irene Mattioli, Matteo Mazzetti, Edoardo Biancalana (Azienda Ospedaliero Universitaria Careggi Firenze, SOD Medicina Interna Interdisciplinare); Gianni Biolo,

Giacomo Bartelloni, Ilaria Martini (Azienda Sanitaria Universitaria Integrata di Trieste, Clinica Medica Generale e Terapia Medica); Matteo Pirro, Graziana Lupattelli, Vanessa Bianconi, Riccardo Alcidi, Alessia Giotta, Massimo R. Mannarino (Azienda Ospedaliera Santa Maria della Misericordia, Perugia, Medicina Interna, Angiologia Malattie da Arteriosclerosi); Domenico Girelli, Fabiana Busti, Giacomo Marchi (Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Medicina d'Urgenza); Nicola Veronese, Mario Barbagallo, Ligia Dominguez, Vincenza Beneduce, Federica Cacioppo, Stefano Ciriminna, Andrea Asaro, Chiara Giannettino, Claudia Canizzo, Giovanna Ottavia Plano, Anna Fazzari, Alessandra Lo Nigro, Ilenia Imbraguglio, Sofia Contorno (Azienda Ospedaliera Universitaria Policlinico Giaccone Policlinico di Palermo, Palermo, Unità Operativa di Geriatria e Lungodegenza); Salvatore Corrao, Giuseppe Natoli, Salvatore Mularo, Valentina Orlando, Giacomo Corrao, Fabio Falcone, Salvatore Scibetta, Luigi Mirarchi, Simona Amodeo, Brenda Bongiorno (A.R.N.A.S. Civico, Di Cristina, Benfratelli, Palermo, UOC Medicina Interna ad Indirizzo Geriatrico-Riabilitativo); Marco Zoli, Maria Laura Maticena, Giuseppe Orio, Eleonora Magnolfi, Giovanni Serafini, Mattia Brunori, Ilaria Lazzari, Angelo Simili (Azienda Ospedaliera Universitaria Policlinico S. Orsola-Malpighi, Bologna, Unità Operativa di Medicina Interna Zoli); Tiziano Lucchi, Paola Nicolini, Gabriele Ghidini, Miriana Martelengo, Maddalena Fabrizi, Giulia Vignani, Arturo Cerizza, Rita Deda, Miriam Zappa (Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Geriatria); Antonio Di Sabatino, Emanuela Miceli, Marco Vincenzo Lenti, Lavinia Pitotti, Valentina Antoci, Ginevra Cambiè, Costanza Caccia Dominioni (IRCCS Policlinico San Matteo di Pavia, Pavia, Clinica Medica I, Reparto 11); Roberto Pontremoli, Valentina Beccati, Giulia Nobili, Giovanna Leoncini, Jacopo Alberto, Federico Cattaneo (IRCCS Azienda Ospedaliera Universitaria San Martino-IST di Genova, Genova, Clinica di Medicina Interna 2); Francesco Cipollone, Maria Teresa Guagnano, Ilaria Rossi, Damiano D'Ardes, Alessia Cipollone, Riccardo Mattia Ricciardi, Marco Bucci, Paola Vizzarri (Ospedale Clinicizzato SS. Annunziata, Chieti, Clinica Medica); Gerardo Mancuso, Daniela Calipari, Mosè Bartone (Ospedale Giovanni Paolo II Lamezia Terme, Catanzaro, Unità Operativa Complessa Medicina Interna); Roberto Manetti, Marta Chiara Sircana, Maria Berria, Alessandro Delitala, Pierluigi Meloni, Silvia Masala (Cliniche San Pietro, Azienda Ospedaliera Universitaria di Sassari, S.C. Clinica Medica); Maurizio Muscaritoli, Alessio Molfini, Antonella Giorgi, Christian Gracin, Giovanni Imbimbo, Carmen Gallicchio, Ottavio Martellucci, Antonietta Gigante, Chiara D'Elia (Policlinico Umberto I, Sapienza Università di Roma, Medicina Interna e Nutrizione Clinica Policlinico Umberto I); Alessandra Marengoni, Thelma Geneletti, Eleonora Carlotti, Arianna Pagani, Claudia Capelli (SC Geriatria, Spedali Civili, Montichiari, Brescia); Antonio Picardi, Umberto Vespasiani Gentilucci, Paolo Gallo, Jessica Avagliano, Francesca Terracciani (Università Campus Bio-Medico, Roma, Medicina Clinica-Epatologia); Giuseppe Bellelli, Maurizio Corsi, Lavinia Vitali, Armida Soccali (Università degli Studi di Milano-Bicocca e Unità Operativa Complessa di Geriatria, IRCCS Fondazione S. Gerardo, Monza); Franco Arturi, Elena Succurro, Melania Melina, Federica Giofrè, Francesca Cosentino, Delia Chiarello, Francesco Andreozzi (Università degli Studi Magna Graecia, Azienda Ospedaliera-Universitaria "Renato Dulbecco", Catanzaro, Unità Operativa Complessa di Medicina Interna); Antonio Brucato Teresa De Falco, Enrica Negro, Martino Brenna, Lucia Trotta, Giovanni Lorenzo Squintani, Giacomo Iacomelli, Giulia Colazzo (ASST Fatebenefratelli—Sacco, Milano, Medicina Interna); Paolo Simioni, Irene Bertozzi, Sara Angela Malerba, Camilla Portinari, Giordano Antonello, Cecilia Fortino, Camilla Goffi, Francesca Guidolin (Azienda Ospedaliera Università di Padova, Padova, Clinica Medica I); Roberto Manfredini, Benedetta Boari, Alfredo De Giorgi, Ruana Tiseo, Giulia Marta Viglione, Caterina Savriè (Azienda Ospedaliera—Universitaria Sant'Anna, Ferrara, Unità Operativa Clinica Medica); Giuseppe Paolisso, Maria Rosaria Rizzo, Claudia

Catalano, Irene Di Meo, Michele Cerasuolo (*Azienda Ospedaliera Universitaria Luigi Vanvitelli- Università della Campania Luigi Vanvitelli, Napoli, Unità Operativa Complessa di Geriatria e Medicina Interna*); Claudio Borghi, Federica Piani, Federico Ruscelli, Chiara Baldini, Giulia Boni (*Medicina Interna Cardiovascolare, IRCCS Azienda Ospedaliero-Universitaria di Bologna*); Carlo Sabbà, Francesco Saverio Vella, Patrizia Suppressa, Alessio Comitangelo, Emanuele Amoroso, Carlo Custodero, Giuseppe Re, Chiara Maria Palmisano (*Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Medicina Interna Universitaria C. Frugoni*); Luigi Fenoglio, Giulia Racca, Alessia Valentina Giraudo, Salvatore D'Agnano, Giorgia Sasia, Irene Ruocco, Floriana Mao, Alice Ferrua (*Azienda Sanitaria Ospedaliera Santa Croce e Carle di Cuneo, Cuneo, S. C. Medicina Interna*); Anna Ludovica Fracanzani, Silvia Tiraboschi, Annalisa Cespiati, Giovanna Oberti, Giordano Sigon, Felice Cinque, Lucia Colavolpe, Jaqueline Currà, Francesca Alletto, Natalia Scaramellini, Simona Leoni, Alessandra Danuta Di Mauro, Gianpaolo Benzoni, Margherita Re, Laura Vivi, Valentina Scime (*Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, UOC Medicina Generale ad Indirizzo Metabolico*); Flora Peyvandi, Raffaella Rossio, Giulia Colombo, Pasquale Agosti, Erica Pagliaro (*Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Medicina Interna 2, Ematologia non tumorale e Coagulopatie*); Ciro Canetta, Valeria Savojardo, Giuliana Ceriani, Christian Folli (*Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Medicina Interna Alta Intensità di Cure*); Fabrizio Montecucco, Cristina Michelauz, Elisa Schiavetta, Chiara Olivero, Simone Isoppo, Curzia Tortorella, Federico Carbone, Luca Liberale, Aurora Mazzocato (*IRCCS Ospedale Policlinico San Martino e Università di Genova, Genova, Clinica Medica 1, Medicina Interna e Specialità Mediche*); Nicola Lucio Liberato, Tiziana Tognin (*ASST di Pavia, UOSD Medicina Interna, Ospedale di Casorate Primo, Pavia*); Francesco Purrello, Antonino Di Pino, Salvatore Piro, Maurizio Di Marco, Nicoletta Miano, Sabrina Scilletta (*Ospedale Garibaldi Nesima, Catania, Unità Operativa Complessa di Medicina Interna*); Renzo Rozzini, Francesca Mazzeo, Giulia Cono, Giulia Cesaroni (*Ospedale Poliambulanza, Brescia, Medicina Interna e Geriatria*); Giuseppe Montrucchio, Paolo Peasso, Edoardo Favale, Cesare Poletto, Carl Margaria, Maura Sanino, Valeria Bianchi, Beatrice Bovo, Beatrice Brusasco, Gabriele Giuliano, Marco Angelieri (*Dipartimento di Scienze Mediche, Università di Torino, Città della Scienza e della Salute, Torino, Medicina Interna 2 Unità Indirizzo d'Urgenza*); Luigina Guasti, Francesca Rotunno, Luana Castiglioni, Andrea Maresca, Leonardo Campiotti, Alessandra Grossi, Roberto Davide Diprizio, Francesco Dentali, Veronica Behnke, Gloria Cuni (*Università degli Studi dell'Insubria, Ospedale di Circolo e Fondazione Macchi, Varese, Medicina e Geriatria*); Marco Bertolotti, Chiara Mussi, Giulia Lancelotti, Laura Orlandi, Federica Di Zio, Gabriele Luppi, Francesca D'Imprima, Chiara Mazza, Claudia Grandi, Chiara Ferrari, Ambrogio Breschi (*Università di Modena e Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena; Ospedale Civile di Baggiovara, Unità Operativa di Geriatria*); Angela Sciacqua, Maria Perticone, Raffaele Maio, Aleandra Scozzafava, Valentino Condoleo, Elvira Clausi, Giuseppe Armentaro, Alberto Panza, Alessia Grandinetti, Maria Rosa, Carlo Alberto Pastura (*Università Magna Graecia Policlinico Renato Dulbecco, Catanzaro, Unità Operativa Malattie Cardiovascolari Geriatriche*); Gianluca Moroncini, Emanuele Filippini, Devis Benfaremo (*Clinica Medica, Azienda Ospedaliera- Universitaria delle Marche, Ancona*); Pietro Castellino, Luca Zanolì, Agostino Gaudio, Anastasia Xourafa, Concetta Spichetti, Serena Torre, Alfio Gennaro, Lucrezia Taibi, Francesca Ferrari (*Azienda Ospedaliera Universitaria Policlinico – V. Emanuele, Catania, Dipartimento di Medicina*); Guido Moreo, Silvia Prolo, Gloria Pina, Lorenzo Magni, Sophia Ratzinger (*Clinica San Carlo Casa di Cura Polispecialistica, Paderno Dugnano, Milano, Unità Operativa di Medicina Generale Emilio Bernardelli*); Alberto Ballestrero, Fabio Ferrando, Roberta Gonella, Arianna Piccardo, Andrea Bellodi, Dejvis Kalaja (*Clinica Di Medicina Interna ad*

Indirizzo Oncologico, Azienda Ospedaliera Università San Martino di Genova); Anna Linda Patti, Giuseppe Famularo, Patrizia Tarsitani, Tiziana Morretti, Andrea Aglitti (*Azienda Ospedaliera San Camillo Forlanini, Roma, Medicina Interna II*); Marcello Giuseppe Maggio, Fulvio Lauretani, Marco Salvi, Chiara Cattabiani, Elena Bronzoni, Aida Hoxha, Beatrice Tanzi (*Azienda Ospedaliero Universitaria di Parma, U.O.C Clinica Geriatrica*); Stefano Del Giacco, Davide Firinu, Giulia Costanzo, Andrea Giovanni Ledda, Matteo Benuzzi, Salvatore Chessa (*Policlinico Universitario Duilio Casula, Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Medicina Interna, Allergologia ed Immunologia Clinica*); Anna Licata, Giuseppe Montalto, Filippo Alessandro Montalto, Angelo Rizzo, Silvia Como, Valentina Virzi (*Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, UOC di Medicina Interna*); Giorgio Basile, Antonino Catalano, Federica Bellone, Concetto Principato, Angelo Cocuzza, Annamaria Buda, Francesco Corica (*Azienda Ospedaliera Universitaria Policlinico G. Martino, Messina, Unità Operativa di Geriatria*); Lorenzo Malatino, Benedetta Stancanelli, Valentina Terranova, Salvatore Di Marca, Rosario Di Quattro, Lara La Malfa, Rossella Caruso, Ivan Isaia, Federica Castelletti, Matteo Regolo, Clara Salmeri, Nicolas Cardaci, Alessandra Lanzafame (*Azienda Ospedaliera per l'Emergenza Cannizzaro, Catania, Clinica Medica Università di Catania*); Patrizia Mecocci, Carmelinda Ruggiero, Virginia Boccardi (*Università degli Studi di Perugia-Azienda Ospedaliera S.M. della Misericordia, Perugia, Struttura Complessa di Geriatria*); Pietro Minuz, Luigi Fondrieschi, Sarah Morellini, Andrea Sartorio (*Azienda Ospedaliera Universitaria Verona, Policlinico GB Rossi, Verona, Medicina Generale per lo Studio ed il Trattamento dell'Ipertensione Arteriosa*); Mario Pirisi, Gian Paolo Fra, Daniele Sola, Mattia Bellan (*Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Medicina Interna 1*); Emilio Simeone, Rosa Scurti, Fabio Tolloso (*Ospedale Civile Santo Spirito di Pescara, Geriatria*); Roberto Tarquini, Alice Valoriani, Silvia Dolenti, Giulia Vannini, Francesco Cei, Marco Gucci, Antonella Fardus Al Refaie, Virginia Morelli, Fabio Salvadori (*Ospedale San Giuseppe, Empoli, USL Toscana Centro, Medicina Interna I*); Sergio Harari, Chiara Lonati, Federico Napoli, Italia Aiello, Gabriele Tarallo, Chiara Apostolico (*Clinica Medica a indirizzo cardio-respiratorio, Multimediale IRCCS, Milano*); Ferdinando Carlo Sasso, Teresa Salvatore, Lucio Monaco, Carmen Riconzi, Francesca Coviello, Maria Elena Corona, Giovanni Di Lorenzo, Serafina Schettino, Christian Catalini, Davide Nilo (*Policlinico Università della Campania L. Vanvitelli, UOC Medicina Interna*); Ilaria Indiano, Alberto Pilotto, Federica Gandolfo, Davide Gonella, Federica Cacioppo (*Ente Ospedaliero Ospedali Galliera Genova, SC Geriatria Dipartimento Cure Geriatriche, Neurologiche e Riabilitazione*); Moreno Tresoldi, Enrica Bozzolo, Sarah Damanti, Gaia Deonette, Giulia Marazzi, Rita Venezia, Lorenzo Ciocca, Jasmin Mahajne, Chiara Calabrese, Giusy Faggiano, Marta Secci, Martina Laffranchi, Ilaria Vergine, Alessandro Marinosci, Cecilia Bussolari, Giovanni Benanti, Francesca Conti, Filippo Sciammetta, Rabia Saeedbhathi (*IRCCS Ospedale San Raffaele – Milano, Medicina Generale e delle Cure Avanzate*); Paolo Pasquero, Massimo Porta, Miriam Gino, Stefania Morra Di Cella, Bianca Pari, Edoardo Pace, Alessandro De Salve (*AOU Città della Salute e della Scienza di Torino – Torino, Medicina Interna IU*); Patrizia Tilocca, Sebastiana Maria Atzori (*Azienda Ospedaliero Universitaria di Sassari– Sassari, Geriatria*); Alberto Moggi Pignone, Giulia Bandini, Maria Cristina De Santis, Chiara Di Cencio, Anna Lo Cricchio (*Azienda Ospedaliero Universitaria Careggi Firenze, Firenze, Medicina Interna 4*); Maria Lorenza Muiesan, Carolina De Ciuceis, Stefano Tenore, Fabio Cherubini, Francesco Russomanno (*Spedali Civili di Brescia, Brescia, Medicina Generale 2*); Nicola Liuzzi, Sokol Rrodhe, Alice Parisi, Eleonora Croce (*Ospedale Civile “Edoardo Agnelli” Pinerolo–Torino, Medicina Generale*); Fiammetta Pagnozzi, Emanuela Messa, Francesca Gaia Bacchieri (*Ospedale Civico di Chivasso ASL Torino 4, Torino, S.C. Medicina Interna*); Gaetano Serviddio, Antonino Davide Romano (*Ospedali Riuniti di Foggia, Foggia, UOC Epatologia a Direzione*

Universitaria); Gianluigi Vendemiale, Francesco Bellanti, Aurelio Lo Buglio (*Azienda Ospedaliero-Universitaria Policlinico Riuniti di Foggia, Foggia, UOC Medicina Interna e dell'Invecchiamento*); Antonino Tuttolomondo, Domenico Di Raimondo, Edoardo Pirera, Riccardo De Rosa (*Azienda Ospedaliera Universitaria Policlinico Giaccone Policlinico di Palermo, Palermo, UOC di Medicina Interna con Stroke Care*); Francesca Dassie, Angelo Di Vincenzo, Sara Brandolese (*Azienda Ospedaliera Università di Padova, Padova, UOC Clinica Medica III*); Agostino Di Ciaula, Carlo Custodero, Antonino Noto, Chiara Valentina Luglio, Piero Portincasa (*Azienda Ospedaliero-Universitaria Policlinico di Bari, Bari, Medicina Interna Universitaria "Augusto Murri"*); Leonardo A. Sechi, Cristiana Catena, Gabriele Brosolo, Stefano Marcante, Andrea Da Porto, Luca Bulfone, Antonio Vacca (*Azienda Sanitaria Universitaria Friuli Centrale, Università di Udine, Dipartimento di Medicina, Clinica Medica, Udine*); Angelo Baldassare Cefalù, Antonina Giammanco, Carola Maria Gagliardo (*Azienda Ospedaliera Universitaria Policlinico Giaccone Policlinico di Palermo, Palermo, UOC di Astanteria e MCAU*); Elena Campello, Chiara Simion (*Azienda Ospedaliera Università di Padova, Padova, Medicina Generale a Indirizzo Trombotico e Emorragico*); Michela Zanetti, Paolo De Colle (*Azienda Sanitaria Universitaria Integrata di Trieste, SC(UCO) Geriatria*).

Author contributions Conceptualization: Roberto Manetti, Marta Chiara Sircana, Alessandro Nobili, Mauro Tettamanti. Methodology: Marta Chiara Sircana, Roberto Manetti, Alfredo Caturano, Mauro Tettamanti, Alessandro Nobili. Formal analysis: Mauro Tettamanti, Sara Ratti. Investigation: REPOSI Investigators. Writing—original draft preparation: Marta Chiara Sircana, Roberto Manetti. Writing—review and editing: Roberto Manetti, Marta Chiara Sircana, Alfredo Caturano, Alessandro Nobili, Mauro Tettamanti, Sara Ratti, Francesca Innocenti, Pier Mannuccio Mannucci. All authors have read and agreed to the published version of the manuscript.

Funding Open access funding provided by Università degli Studi di Sassari within the CRUI-CARE Agreement. None.

Data availability The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Informed consent Written informed consent was obtained from all patients involved in the study.

Declaration of generative AI and AI-assisted technologies in the writing process The authors did not use generative AI and AI-assisted technologies in the writing process.

Ethical approval and Human animal rights The study protocol was approved by the Ethics Committee of the coordinating center and subsequently endorsed by the local Ethics Committees of all participating hospitals.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are

included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Arina P, Hofmaenner DA, Singer M (2024) Definition and epidemiology of sepsis. *Semin Respir Crit Care Med* 45(04):461–468. <https://doi.org/10.1055/s-0044-1787990>
2. Zizzo G, Guazzardi G, Bompane D, Di Terlizzi F, Rotola G, Stefani I et al (2025) Sepsis in internal medicine: blood culture-based subtypes, hospital outcomes, and predictive biomarkers. *Front Med* 12:1503868. <https://doi.org/10.3389/fmed.2025.1503868>
3. Zaccone V, Tosoni A, Passaro G, Vallone CV, Impagnatiello M, Li Puma DD et al (2017) Sepsis in internal medicine wards: current knowledge, uncertainties and new approaches for management optimization. *Ann Med* 49(7):582–592. <https://doi.org/10.1080/07853890.2017.1332776>
4. Fortini A, Faraone A, Meini S, Bettocchi M, Longo B, Valoriani B et al (2021) Validity of 'Sepsis-3' criteria in identifying patients with community-onset sepsis in internal medicine wards; a prospective, multicenter study. *Eur J Intern Med* 85:92–97. <https://doi.org/10.1016/j.ejim.2020.12.025>
5. La Via L, Sangiorgio G, Stefani S, Marino A, Nunnari G, Cocuzza S et al (2024) The global burden of sepsis and septic shock. *Epidemiol* 5(3):456–478. <https://doi.org/10.3390/epidemiologia5030032>
6. Grande E, Grippo F, Frova L, Pantosti A, Pezzotti P, Fedeli U (2019) The increase of sepsis-related mortality in Italy: a nationwide study, 2003–2015. *Eur J Clin Microbiol Infect Dis* 38(9):1701–1708. <https://doi.org/10.1007/s10096-019-03601-3>
7. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS et al (2016) Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 315(8):775. <https://doi.org/10.1001/jama.2016.0289>
8. Putot A, Prendki V (2023) New horizons in sepsis management in older patients. *Age Ageing* 52(2):afad016. <https://doi.org/10.1093/ageing/afad016>
9. Qiu X, Lei YP, Zhou RX (2023) SIRS, SOFA, qSOFA, and NEWS in the diagnosis of sepsis and prediction of adverse outcomes: a systematic review and meta-analysis. *Expert Rev Anti Infect Ther* 21(8):891–900. <https://doi.org/10.1080/14787210.2023.2237192>
10. Okoye C, Piazzoli A, Ferrara MC, Finazzi A, Ornago AM, Pinardi E et al (2025) Enhancing in-hospital mortality prediction in older patients with sepsis: the role of frailty indices and multidrug-resistance status in non-ICU wards—a proof-of-concept study. *Aging Clin Exp Res* 37(1):45. <https://doi.org/10.1007/s40520-025-02955-3>
11. Liu W, Hu C, Zhao S (2022) Sarcopenia and mortality risk of patients with sepsis: a meta-analysis. *Int J Clin Pract* 2022(1):4974410. <https://doi.org/10.1155/2022/4974410>
12. Ferré C, Llopis F, Martín-Sánchez FJ, Cabello I, Albert A, García-Lamberechts EJ et al (2022) The utility of the Barthel index as an outcome predictor in older patients with acute infection attending the emergency department. *Australas Emerg Care* 25(4):316–320. <https://doi.org/10.1016/j.auec.2022.03.003>
13. Lanza ST, Cooper BR (2016) Latent class analysis for developmental research. *Child Dev Perspect* 10(1):59–64. <https://doi.org/10.1111/cdep.12163>

14. Mannucci PM, Nobili A, Pasina L (2018) Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. *Intern Emerg Med* 13(8):1191–1200. <https://doi.org/10.1007/s11739-018-1941-8>
15. Rockwood K, Mitnitski A (2007) Frailty in relation to the accumulation of deficits. *J Gerontol A Biol Sci Med Sci* 62(7):722–727. <https://doi.org/10.1093/gerona/62.7.722>
16. Cesari M, Franchi C, Cortesi L, Nobili A, Ardoino I, Mannucci PM (2018) Implementation of the frailty index in hospitalized older patients: results from the REPOSI register. *Eur J Intern Med* 56:11–18. <https://doi.org/10.1016/j.ejim.2018.06.001>
17. Centers for disease control and prevention. International classification of diseases, ninth revision, clinical modification (ICD-9-CM) [Classification manual] [Internet]. Atlanta, GA: centers for disease control and prevention; 2011 [cited 2026 Jan 11]. Available from: https://archive.cdc.gov/www_cdc_gov/nchs/icd/icd9cm.htm
18. World health organization collaborating centre for drug statistics methodology. ATC/DDD Index [Drug classification system] [Internet]. Oslo, Norway: WHO Collaborating centre for drug statistics methodology; 2024 [cited 2026 Jan 11]. Available from: https://atcddd.fhi.no/atc_ddd_index/
19. Hagenaars JA, McCutcheon AL (eds) (2002) Applied latent class analysis, 1st ed. Cambridge University Press. <https://doi.org/10.1017/CBO9780511499531>
20. Boustani M, Campbell N, Munger S, Maidment I, Fox C (2008) Impact of anticholinergics on the aging brain: a review and practical application. *Aging Health* 4(3):311–320. <https://doi.org/10.2217/1745509X.4.3.311>
21. Kopczynska M, Sharif B, Cleaver S, Spencer N, Kurani A, Lee C et al (2018) Red-flag sepsis and SOFA identifies different patient population at risk of sepsis-related deaths on the general ward. *Medicine (Baltimore)* 97(49):e13238. <https://doi.org/10.1097/MD.00000000000013238>
22. Szakmany T, Lundin RM, Sharif B, Ellis G, Morgan P, Kopczynska M et al (2016) Sepsis prevalence and outcome on the general wards and emergency departments in wales: results of a multi-centre, observational point prevalence study. *PLoS ONE* 11(12):e0167230. <https://doi.org/10.1371/journal.pone.0167230>
23. Darbà J, Marsà A (2020) Epidemiology, management and costs of sepsis in Spain (2008–2017): a retrospective multicentre study. *Curr Med Res Opin* 36(7):1089–1095. <https://doi.org/10.1080/03007995.2020.1760809>
24. Torvik MA, Nymo SH, Bjørnsen LP, Kvarenes HW, Ofstad EH (2023) Patient characteristics in sepsis-related deaths: prevalence of advanced frailty, comorbidity, and age in a Norwegian hospital trust. *Infection* 51(4):1103–1115. <https://doi.org/10.1007/s15010-023-02013-y>
25. Nates JL, Pène F, Darmon M, Mokart D, Castro P, David S et al (2024) Septic shock in the immunocompromised cancer patient: a narrative review. *Crit Care* 28(1):285. <https://doi.org/10.1186/s13054-024-05073-0>
26. Lan Y, Zhu J, Pu P, Ni W, Yang Q, Chen L (2024) Association of dementia with the 28-day mortality of sepsis: an observational and Mendelian randomization study. *Front Aging Neurosci* 16:1417540. <https://doi.org/10.3389/fnagi.2024.1417540>
27. Ibarz M, Haas LEM, Ceccato A, Artigas A (2024) The critically ill older patient with sepsis: a narrative review. *Ann Intensive Care* 14(1):6. <https://doi.org/10.1186/s13613-023-01233-7>. (PubMed PMID:38200360; PubMed Central PMCID:PMC10781658)
28. Zador Z, Landry A, Cusimano MD, Geifman N (2019) Multimorbidity states associated with higher mortality rates in organ dysfunction and sepsis: a data-driven analysis in critical care. *Crit Care* 23(1):247. <https://doi.org/10.1186/s13054-019-2486-6>
29. Taylor SP, Bray BC, Chou SH, Burns R, Kowalkowski MA (2022) Clinical subtypes of sepsis survivors predict readmission and mortality after hospital discharge. *Ann Am Thorac Soc* 19(8):1355–1363. <https://doi.org/10.1513/AnnalsATS.202109-1088OC>
30. Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D (2020) Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019—results from a systematic review and meta-analysis. *Crit Care* 24(1):239. <https://doi.org/10.1186/s13054-020-02950-2>
31. Esteban A, Frutos-Vivar F, Ferguson ND, Peñuelas O, Lorente JA, Gordo F et al (2007) Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. *Crit Care Med* 35(5):1284–1289. <https://doi.org/10.1097/01.CCM.00000260960.94300.DE>
32. Bai Z, Lai Y, Han K, Shi L, Guan X, Xu Y (2024) Human albumin for adults with sepsis: an updated systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)* 103(52):e40983. <https://doi.org/10.1097/MD.00000000000040983>
33. Wang W, Chen W, Liu Y, Li L, Li S, Tan J et al (2021) Blood glucose levels and mortality in patients with sepsis: dose–response analysis of observational studies. *J Intensive Care Med* 36(2):182–190. <https://doi.org/10.1177/0885066619889322>
34. Candel BGJ, Raven W, Lameijer H, Thijssen WAMH, Termorshuizen F, Boerma C et al (2022) The effect of treatment and clinical course during emergency department stay on severity scoring and predicted mortality risk in intensive care patients. *Crit Care* 26(1):112. <https://doi.org/10.1186/s13054-022-03986-2>
35. Skei NV, Nilsen TIL, Mohus RM, Prescott HC, Lydersen S, Solligård E et al (2023) Trends in mortality after a sepsis hospitalization: a nationwide prospective registry study from 2008 to 2021. *Infection* 51(6):1773–1786. <https://doi.org/10.1007/s15010-023-02082-z>
36. Edwards L, Nelves E, Ardissino M, Lin Jia Qi H, Jhanji S, Antcliffe DB et al (2025) The evolution of mortality from sepsis in patients with cancer: a systematic review and meta-analysis. *J Intensive Care Soc*. <https://doi.org/10.1177/17511437251363762>
37. Arvaniti V, D’Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M et al (2010) Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. *Gastroenterology* 139(4):1246–1256.e5. <https://doi.org/10.1053/j.gastro.2010.06.019>
38. Walkey AJ, Wiener RS (2014) Hospital case volume and outcomes among patients hospitalized with severe sepsis. *Am J Respir Crit Care Med* 189(5):548–555. <https://doi.org/10.1164/rccm.201311-1967OC>
39. Braithwaite E, Todd OM, Atkin A, Hulatt R, Tadrous R, Alldred DP et al (2023) Interventions for reducing anticholinergic medication burden in older adults—a systematic review and meta-analysis. *Age Ageing* 52(9):afad176. <https://doi.org/10.1093/ageing/afad176>
40. Meyer NJ, Prescott HC (2024) Sepsis and Septic Shock. *N Engl J Med* 391(22):2133–2146. <https://doi.org/10.1056/NEJMra2403213>
41. Chen YS, Liao TY, Hsu TC, Hsu WT, Lee MTG, Lee CC (2020) Temporal trend and survival impact of infection source among patients with sepsis: a nationwide study. *Crit Care Resusc* 22(2):126–132. <https://doi.org/10.51893/2020.2.0a2>
42. Putot A, Garin N, Rello J, Prendki V (2025) Comprehensive management of pneumonia in older patients. *Eur J Intern Med* 135:14–24. <https://doi.org/10.1016/j.ejim.2025.02.025>
43. Tandogdu Z, Koves B, Ristovski S, Balci MBC, Rennesund K, Gravas S et al (2024) Urosepsis 30-day mortality, morbidity, and their risk factors: SERPENS study, a prospective, observational multi-center study. *World J Urol* 42(1):314. <https://doi.org/10.1007/s00345-024-04979-2>
44. Rudd KE, Randolph AG, Angus DC, Bauer M, Chesley CF, Filbin MR et al (2025) Preventing, identifying, and managing sepsis in

- the community: research and clinical priorities. *Lancet Prim Care* 1(1):100010. <https://doi.org/10.1016/j.lanprc.2025.100010>
45. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med* 47(11):1181–1247. <https://doi.org/10.1007/s00134-021-06506-y>
 46. Abdul-Aziz MH, Hammond NE, Brett SJ, Cotta MO, De Waele JJ, Devaux A et al (2024) Prolonged vs intermittent infusions of β -lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis. *JAMA* 332(8):638. <https://doi.org/10.1001/jama.2024.9803>
 47. Bassetti M, Rello J, Blasi F, Goossens H, Sotgiu G, Tavošchi L et al (2020) Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. *Int J Antimicrob Agents* 56(6):106184. <https://doi.org/10.1016/j.ijantimicag.2020.106184>
 48. Chang SW, Choi J, Oh JY, Lee YS, Min KH, Hur GY et al (2025) Fluid resuscitation and initial management in patients presenting with sepsis in the general ward. *Life* 15(1):124. <https://doi.org/10.3390/life15010124>
 49. World Health Organization (eds) (2024). Guidelines for the prevention of bloodstream infections and other infections associated with the use of intravascular catheters: part 1: Peripheral catheters. Geneva: World Health Organization. p 1

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.